Disclosed is a reagent for prothrombin time measurement, containing a tissue factor and a surfactant, wherein the value of formula (I), which is represented by (surfactant amount (mol))/(total protein amount (g)), is 0.013 to 0.05 mol/g.

A blood coagulation analyzing method according to one or more aspects may include: calculating a coagulation time based on data representing a coagulation curve of a change in an optical detection value of a blood specimen added with a reagent for starting a coagulation reaction; calculating an index value related to derivatives calculated concerning the coagulation curve represented by the data used in the calculating the coagulation time; and determining whether an early reaction error has occurred based on a comparison result obtained by comparing the index value to a predetermined threshold.

Test strips for determining the activity of a coagulation factor in a blood sample are provided. The strip comprises a support, a sample inlet port for deposition of a blood sample, and a reaction area comprising a blood coagulation reagent. The sample inlet port is connected to the reaction area, and the coagulation reagent comprises blood plasma deficient in the coagulation factor for which activity is to be measured, an ionic citrate source an ionic calcium source, and either one or more coagulation contact phase activator reagents and phospholipids or a mixture of tissue factor and phospholipids. The disclosure further relates to in vitro methods for measuring an activity of a coagulation factor.

Novel inhibitors of the Tissue Factor-Protease Activated Receptor 2 (TF-PAR2) signaling pathway for use in the treatment or prevention of heart failure (HF). In-vitro method for identifying a subject at risk for developing ischemic heart failure (IHF) or adverse remodeling following myocardial infarction (MI), comprise the steps of (i) determining the tissue factor (TF) cytoplasmic domain phosphorylation in myeloid cells and the levels of active TGF-?1 in a biological sample collected from said subject, and (ii) comparing the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-?1 in said biological sample with the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-?1 in a normal, healthy subject, wherein increased levels of phosphorylation of the TF cytoplasmic domain and active TGF-?1 are indicative for an increased risk of developing IHF or adverse remodeling following MI.

Test strips for determining the activity of a coagulation factor in a blood sample are provided. The strip comprises a support, a sample inlet port for deposition of a blood sample, and a reaction area comprising a blood coagulation reagent. The sample inlet port is connected to the reaction area, and the coagulation reagent comprises blood plasma deficient in the coagulation factor for which activity is to be measured, an ionic citrate source an ionic calcium source, and either one or more coagulation contact phase activator reagents and phospholipids or a mixture of tissue factor and phospholipids. The disclosure further relates to in vitro methods for measuring an activity of a coagulation factor.

Test strips for determining the activity of a coagulation factor in a blood sample are provided. The strip comprises a support, a sample inlet port for deposition of a blood sample, and a reaction area comprising a blood coagulation reagent. The sample inlet port is connected to the reaction area, and the coagulation reagent comprises blood plasma deficient in the coagulation factor for which activity is to be measured, an ionic citrate source an ionic calcium source, and either one or more coagulation contact phase activator reagents and phospholipids or a mixture of tissue factor and phospholipids. The disclosure further relates to in vitro methods for measuring an activity of a coagulation factor.

The present invention provides a tissue factor (TF) monoclonal antibody and a preparation method therefor. The monoclonal antibody provided by the present invention can specifically bind with a TF antigen, has high affinity and low immunogenicity, and has the activity of resisting tumors and the like.

The present invention is in the field of blood coagulation diagnostics and relates to an improved method for quantitatively determining fibrinogen in a sample. The method comprises adding factor XIII to the reaction mixture.

The present invention provides a pipette tip, which can be used in in-vitro diagnostics, in particular in the diagnostic testing of body fluids, such as in coagulation testing. The Pipette tip contains two constituents in a spatially separated manner. The present invention furthermore provides a method of performing such diagnostics, e.g. coagulation analysis, and to the use of the pipette tip in such diagnostic testing.

The present invention concerns the use of immunoassays for the characterisation, diagnosis, screening and monitoring of cancer and other diseases. In particular said immunoassays involve the use of polyclonal and monoclonal antibodies against different regions in tissue factor, particularly urinary tissue factor, and methods for generating the same. Preferably said antibodies are specific for the tissue factor signal transduction peptide region (anti-TF-STP antibodies). In particular, the present invention relates to antibodies and the use thereof which are specific for phosphorylated isoforms of TF-STP. The invention further concerns use of these anti-TF-STP antibodies to quantitate TF-STP isoforms in biological fluids, in particular urine. Also described herein is the use of said antibodies in immunoassays for the characterisation, diagnosis, screening and monitoring of cancer and other diseases, specific polyclonal and monoclonal antibodies against different regions in tissue factor, and methods for generating the same.